Oligonucleotide Synthesis, Modification, and Purification Services Market Size, Share & Trends Analysis Report By Product (Primers, Probes, DNA Oligos, RNA Oligos, Others), By Application (Therapeutic Applications (Neurological Disorders, Rare Diseases, Other Diseases), Research Applications (PCR, Sequencing, Other Research Applications), Diagnostic Applications), Type, End-users, By Region, And By Segment Forecasts, 2025-2034

Oligonucleotide Synthesis, Modification, and Purification Services Market Size is valued at USD 4.69 billion in 2024 and is predicted to reach USD 12.27 billion by the year 2034 at a 10.02% CAGR during the forecast period for 2025-2034.

Key Industry Insights & Findings from the Report:

• The increasing focus on understanding genetic mechanisms and developing new therapies drives demand for oligonucleotide synthesis and related services.
• Companies investing in innovative synthesis platforms and purification techniques can capture a larger market share.
• North America dominated the market and accounted for a global revenue share in 2023.
• The cost of oligonucleotide synthesis can be significant, especially for custom or modified sequences. This expense may limit adoption, particularly for smaller research labs or organizations with limited budgets.

Synthetic DNA oligonucleotides are applied in a wide range of applications, from fundamental research to clinical diagnostics and biotherapeutics. Oligonucleotides are chemically synthesized molecular chains from nucleosides. Solid-phase synthesis is the most popular method used for oligonucleotides chemical synthesis. They have a variety of uses in biology, biochemistry, molecular diagnostics, genomics, forensics, and others. Selecting the suitable oligonucleotide synthesizer for application is critical to optimizing product quality while maintaining cost-effectiveness.

The primary elements boosting the growth of the oligonucleotide synthesis, modification, and purification services market include increasing demand for oligonucleotides, growing preference of patients toward personalized medicines, rising collaborations and mergers/acquisitions by manufacturers, and growing older population, and the high prevalence of chronic diseases. Apart from this, the need for high-quality oligos is increasing due to the increase in R&D activities. Therefore, biotech and pharmaceutical companies' increasing research and development activities to treat various viral infections, chronic diseases, and genetic disorders are expected to fuel market growth over the forecast years. 

For instance, in July 2017, Nitto Denko Avecia Inc. (Avecia) opened a new oligonucleotide API manufacturing facility in Milford, MA. The expansion has added 20,000 sq. ft. of manufacturing and office space at the site and provided CGMP oligonucleotide manufacturing capacity up to 1.8 mol, bringing the site capacity to 3.0 mol. Also, this expansion has helped Avecia's clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials. However, the low-quality oligonucleotide sequences, lack of technical requirements, and the complexities associated with the oligonucleotide synthesis may hamper the market growth.

Competitive Landscape

Some Of The Key Players In The Oligonucleotide Synthesis, Modification, and Purification Services Market:

• Agilent Technologies
• Ajinomoto Bio-Pharma Services
• CordenPharma
• Integrated DNA Technologies
• Kaneka Eurogentec
• LGC Biosearch Technologies
• Microsynth
• Merck
• Nitto Avecia
• Thermo Fisher Scientific
• TriLink BioTechnologies
• Creative Biolabs
• Ella Biotech
• Eurofins Genomics
• Future Synthesis
• Ribo Biotechnology
• STA Pharmaceutical
• GE Healthcare
• GeneDesign, Inc.
• Bio-synthesis Inc.
• Almac Group
• Sumitomo Chemical
• Axolabs (LGC Group)
• MilliporeSigma
• BioSpring
• ChemGenes
• BianoScience GmbH
• ATDBio Ltd
• Burkert UK Limited
• IBA Lifesciences GmbH

Market Segmentation

The Oligonucleotide Synthesis, Modification, and Purification Services Market is segmented into product, application, type, and end-users. By product, it includes primers, probes, and DNA oligos, such as molecular beacons, randomer oligos, and more specialized variants like unlocked nucleobase analog (UNA) and twisted intercalating nucleic acid (TINA) oligos, as well as other categories such as light-activated oligos and chimeric oligos. RNA oligos encompass single guide RNA (sgRNA), small interfering RNA (siRNA), microRNA (miRNA), antisense oligos (ASO), sequencing primers, and aptamers. Applications include therapeutic uses for conditions like neurological disorders, rare diseases, and other medical conditions, alongside research applications in PCR, sequencing, and diagnostics. The market is further divided by types into customized oligos, predesigned oligos, reagents & consumables, and equipment. End-users span across hospitals, pharmaceutical and biotechnology companies, diagnostic laboratories, CROs and CMOs, and academic research institutes.

The market is being examined throughout North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Due to increased R&D investments in pharma and biotech businesses to enhance oligonucleotide production and synthesis processes, North America is likely to have the largest share of this market throughout the forecast years, followed by Europe.

Recent Developments:

• In October 2023, Integrated DNA Technologies established a new production facility for therapeutic oligonucleotides in Iowa, USA. Customers will benefit from expanded research and manufacturing capabilities and knowledge provided by the 41,000 square foot facility.

The Oligonucleotide Synthesis, Modification, and Purification Services Market Report Scope